Upstream Bio snags $200m Series A
Upstream Bio, a biotech company focused on inflammation, has raised $200 million in Series A financing.
Upstream Bio, a biotech company focused on inflammation, has raised $200 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination